French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years ... This time around, NICE assessed the med using a faster cost comparison process that compared Lynparza ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

for the world’s first and only chikungunya vaccine, Ixchiq. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...